PKCδ-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs
Open Access
- 21 June 2021
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 40 (29) , 4796-4808
Abstract
The tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) have been widely used for non-small cell lung cancer (NSCLC) patients, but the development of acquired resistance remains a therapeutic hurdle. The reduction of glucose uptake has been implicated in the anti-tumor activity of EGFR TKIs. In this study, the upregulation of the active sodium/glucose co-transporter 1 (SGLT1) was found to confer the development of acquired EGFR TKI resistance and was correlated with the poorer clinical outcome of the NSCLC patients who received EGFR TKI treatment. Blockade of SGLT1 overcame this resistance in vitro and in vivo by reducing glucose uptake in NSCLC cells. Mechanistically, SGLT1 protein was stabilized through the interaction with PKCδ-phosphorylated (Thr678) EGFR in the TKI-resistant cells. Our findings revealed that PKCδ/EGFR axis-dependent SGLT1 upregulation was a critical mechanism underlying the acquired resistance to EGFR TKIs. We suggest co-targeting PKCδ/SGLT1 as a potential strategy to improve the therapeutic efficacy of EGFR TKIs in NSCLC patients.Keywords
This publication has 79 references indexed in Scilit:
- Sustained Activation of Protein Kinase C Induces Delayed Phosphorylation and Regulates the Fate of Epidermal Growth Factor ReceptorPLOS ONE, 2013
- Lapatinib-Mediated Cyclooxygenase-2 Expression via Epidermal Growth Factor Receptor/HuR Interaction Enhances the Aggressiveness of Triple-Negative Breast Cancer CellsMolecular Pharmacology, 2013
- Hepatitis B Virus-Encoded X Protein Downregulates EGFR Expression via Inducing MicroRNA-7 in Hepatocellular Carcinoma CellsEvidence-Based Complementary and Alternative Medicine, 2013
- Regulation of Autophagy by Glucose in Mammalian CellsCells, 2012
- LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled TrialClinical Pharmacology & Therapeutics, 2012
- Nuclear PKM2 regulates β-catenin transactivation upon EGFR activationNature, 2011
- A Fluorescence Method for Measurement of Glucose Transport in Kidney CellsDiabetes Technology & Therapeutics, 2011
- Finding a fitting shoe for CinderellaAutophagy, 2010
- Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase ActivityCancer Cell, 2008
- Protein KinaseCδ-Calmodulin Crosstalk Regulates Epidermal Growth Factor Receptor Exit from Early EndosomesMolecular Biology of the Cell, 2004